JPRN-jRCT1091220272已完成2 期
An investigator-initiated phase II study in pleurodesis for secondary intractable pneumothorax with sterile graded talc - J-TALC2
ational Hospital Organization Nagoya Medical Center Hideo Saka0 个研究点目标入组 30 人开始时间: 2017年1月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Patients who are diagnosed with pneumothorax by chest radiography.
- •(2)Patients with any underlying diseases which cause pneumothorax.
- •(3)Patients whose air leakage lasts more than 7 days at the time of case registration without efficacy of thoracic drainage.
- •(4)Patients who are in surgical difficulty at high risk of anesthesia and surgery due to low pulmonary function or other causes, or who experienced repeated relapse without efficacy of surgery with expected low therapeutic effect of second surgery.
- •(5)20 years old or older patients at the time of acquisition of informed consent.
- •(6)Patients who provided written consents for participation in this study by themselves.
排除标准
- •(1)Patients with spontaneous pneumothorax, traumatic pneumothorax or iatrogenic pneumothorax.
- •(2)Patients with a history of hypersensitivity to talc.
- •(3)Patients with severe infection complications.
- •(4)Patients under treatment for heart failure at the time of consent acquisition.
- •(5)Patients with a history of myocardial infarction within 30 days before the time of consent acquisition.
- •(6)Patients with advanced blood coagulation disorder.
- •(7)Patients who are considered to require simultaneous pleurodesis on both sides.
- •(8)Patients with postoperative pulmonary fistula.
- •(9)Patients who are administered systemic corticosteroids (equivalent to 10 mg/day or more of prednisolone) at the time of case registration.
- •(10)Patients with clinically expected sufficient efficacy only by bronchial embolization therapy with EWS.
- •(11)Patients who are pregnant or nursing, who wish to become pregnant during the observation period, or who cannot control contraception.
- •(12)Patients who participated in other trials within 6 months before the time of consent acquisition.
- •(13)Patients whom the principal investigator or other investigators decided not suitable for participation in this study.
研究者
相似试验
已完成
2 期
Investigator-initiated Phase 2 clinical study of S-005151 in patients with osteoarthritis of the kneeOsteoarthritis of the kneeJPRN-jRCT2021200034Ishibashi Yasuyuki20
进行中（未招募）
不适用
A phase I-IIa clinical study on the investigational anticancer drug J1 in patients with advanced cancer. A prospective, single armed, open label, dose-finding phase I-IIa study.Treatment of cancer.MedDRA version: 8Level: HLTClassification code 10029105EUCTR2005-002901-22-SEOncopeptides AB40
进行中（未招募）
1 期
Study of safety and efficacy of genome-edited hematopoietic stem and progenitor cells in sickle cell disease (SCD)EUCTR2019-003489-41-ITOVARTIS PHARMA AG30
进行中（未招募）
1 期
A first-in-human study of UX053 in Patients with Glycogen Storage Disease type III (GSD III)Glycogen Storage Disease Type III (GSD III)MedDRA version: 20.1Level: PTClassification code 10053250Term: Glycogen storage disease type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-000903-19-ITTRAGENYX PHARMACEUTICAL INC.30
进行中（未招募）
1 期
A first-in-human study of UX053 in Patients with Glycogen Storage Disease type III (GSD III)Glycogen Storage Disease Type III (GSD III)MedDRA version: 20.1Level: PTClassification code 10053250Term: Glycogen storage disease type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-000903-19-ESltragenyx Pharmaceutical Inc.30